Abstract
In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.
Keywords: endothelial cells, chronic inflammation, angiogenesis, signal transduction, drugs, pharmacology, vascular drug targeting
Current Vascular Pharmacology
Title: Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases
Volume: 3 Issue: 1
Author(s): Joanna M. Kuldo, Ken Ichi Ogawara, Naomi Werner, Sigridur A. Asgeirsdottir, Jan A. A.M. Kamps, Robbert J. Kok and Grietje Molema
Affiliation:
Keywords: endothelial cells, chronic inflammation, angiogenesis, signal transduction, drugs, pharmacology, vascular drug targeting
Abstract: In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.
Export Options
About this article
Cite this article as:
Kuldo M. Joanna, Ogawara Ichi Ken, Werner Naomi, Asgeirsdottir A. Sigridur, Kamps A.M. Jan A., Kok J. Robbert and Molema Grietje, Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773898
DOI https://dx.doi.org/10.2174/1570161052773898 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Treatment of Pulmonary Thromboembolism in Patients with Systemic Blood Pressure Stability and Right Ventricular Dysfunction
Current Respiratory Medicine Reviews Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Synthesis of Substituted Cinnamido Linked Quinazolinone Congeners as Potential Anticancer Agents via Mitochondrial Dependent Intrinsic Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)
Current Vascular Pharmacology Natural or Plant Products for the Treatment of Neurological Disorders: Current Knowledge
Current Drug Metabolism Hypertension in Older Patients
Current Hypertension Reviews Role of WNK Kinases in Blood Pressure Control
Current Hypertension Reviews Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews The Role of Hypocarbia in the Development of Cystic Periventricular Leukomalacia
Current Pediatric Reviews Pharmacokinetics of Selegiline in a Rabbit Model
Letters in Drug Design & Discovery [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Catheter-directed Thrombolysis <i>versus</i> Systemic Anticoagulation for Submassive Pulmonary Embolism: A Meta-Analysis
Current Cardiology Reviews The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry